ClinicalTrials.gg
Not yet recruitingNCT07692672GIFTUpdated Jul 9, 2026

Intrauterine G-CSF Infusion for Thin Endometrium

A Phase 3 interventional study of Granulocyte Colony-Stimulating Factor(G-CSF) and Normal Saline in Thin Endometrium and Female Infertility, sponsored by Nanjing University. Not yet recruiting. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Nanjing University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
Female
01

Study summary

Thin endometrium is a condition in which the lining of the uterus is too thin during preparation for embryo transfer. This may reduce the chance of pregnancy and live birth in patients undergoing frozen-thawed embryo transfer.

This study will evaluate whether intrauterine infusion of granulocyte colony-stimulating factor, also called G-CSF, can improve pregnancy outcomes in patients with thin endometrium. Participants will be randomly assigned to one of two groups. The experimental group will receive mild endometrial stimulation followed by intrauterine infusion of G-CSF 300 μg. The control group will receive the same mild endometrial stimulation followed by intrauterine infusion of normal saline. Both groups will then continue standard endometrial preparation for frozen-thawed embryo transfer.

The main outcome of the study is the live birth rate. The study will also assess endometrial thickness, endometrial blood flow, clinical pregnancy rate, miscarriage rate, and safety outcomes, including adverse events, pregnancy complications, fetal malformations, and neonatal birth defects. Participants will be followed from enrollment through embryo transfer, pregnancy assessment, and delivery.

This is a single-center, prospective, randomized controlled trial conducted at Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School. The planned sample size is 620 participants.

Read the detailed description

Thin endometrium remains a clinical challenge in assisted reproductive technology because it may reduce endometrial receptivity and the chance of successful embryo implantation and live birth. Several treatment strategies have been used for thin endometrium, including hormonal treatment, medications to improve blood flow, endometrial stimulation, and intrauterine infusion of granulocyte colony-stimulating factor (G-CSF). However, the clinical benefit of intrauterine G-CSF infusion remains uncertain, partly because previous studies have differed in patient populations, timing of administration, dose, and study design.

This study is designed to evaluate whether intrauterine infusion of G-CSF during the endometrial preparation phase can improve reproductive outcomes in patients with thin endometrium undergoing frozen-thawed embryo transfer. The study uses a prospective, single-center, randomized, parallel-group, blinded, superiority design. Eligible participants will be randomly assigned in a 1:1 ratio to receive either mild endometrial stimulation with intrauterine G-CSF infusion or mild endometrial stimulation with intrauterine normal saline infusion. Randomization will be performed using an interactive web response system.

All participants will receive routine endometrial preparation for frozen-thawed embryo transfer according to local clinical practice. In the intervention group, participants will undergo mild endometrial stimulation followed by intrauterine infusion of G-CSF 300 μg. In the control group, participants will undergo the same mild endometrial stimulation procedure followed by intrauterine infusion of an equal volume of normal saline. Participants, outcome assessors, and statistical analysts will be blinded to group assignment, while the physician performing the intrauterine procedure will not be blinded.

After the intrauterine procedure, endometrial development will be monitored by ultrasound. Embryo transfer will be performed after endometrial transformation according to the frozen-thawed embryo transfer protocol. Participants will be followed for pregnancy outcomes, delivery outcomes, and safety events. The study aims to determine whether the addition of intrauterine G-CSF to mild endometrial stimulation provides a clinically meaningful benefit compared with mild endometrial stimulation and saline control.

02

Conditions studied

  • Thin Endometrium
  • Female Infertility

Browse trials for

Keywords

  • Thin Endometrium
  • G-CSF
  • Intrauterine Infusion
  • Frozen-Thawed Embryo Transfer
  • Live Birth Rate
03

In context

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

This study's planned enrollment of 620 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

Nanjing University is the lead sponsor of 21 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to \<40 years.
  • Patients with normal ovarian function.
  • History of endometrial thickness ≤7 mm in at least one previous endometrial preparation cycle.
  • At least two good-quality embryos remaining.
  • Fewer than 3 previous embryo transfer cycles.
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Uterine diseases or conditions that may affect the uterine cavity, including intramural uterine fibroids affecting the uterine cavity, severe adenomyosis, endometriosis, uterine malformation, endometrial tuberculosis, or severe untreated intrauterine adhesions.
  • Endometrial lesions, history of pelvic tumors, or previous radiotherapy or chemotherapy.
  • Known allergy to G-CSF.
  • Current participation in another clinical study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
620 participants (estimated)

Study arms

  • Experimental
    Mild Endometrial Stimulation With Intrauterine G-CSF Infusion

    Participants in this arm will undergo mild endometrial stimulation followed by intrauterine infusion of G-CSF 300 μg during the endometrial preparation cycle for frozen-thawed embryo transfer.

    Biological: Granulocyte Colony-Stimulating Factor(G-CSF)

  • Placebo comparator
    Mild Endometrial Stimulation With Intrauterine Normal Saline Infusion

    Participants in this arm will undergo the same mild endometrial stimulation procedure followed by intrauterine infusion of an equal volume of normal saline during the endometrial preparation cycle for frozen-thawed embryo transfer.

    Drug: Normal Saline

Interventions

  • BiologicalGranulocyte Colony-Stimulating FactorStudies of Granulocyte Colony-Stimulating FactorGranulocyte Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in the experimental arm will receive a single intrauterine infusion of G-CSF 300 μg after mild endometrial stimulation during the endometrial preparation cycle for frozen-thawed embryo transfer.

    Also known as: Recombinant Human Granulocyte Colony-Stimulating Factor

  • DrugNormal Saline

    Participants in the control arm will receive a single intrauterine infusion of an equal volume of normal saline after the same mild endometrial stimulation procedure during the endometrial preparation cycle for frozen-thawed embryo transfer.

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Live Birth Rate

    The proportion of participants who deliver at least one live-born infant after the registered frozen-thawed embryo transfer cycle. Live birth is defined as delivery of at least one newborn with signs of life at 28 weeks of gestation or later.

    Time frame: From embryo transfer to delivery, approximately 40 weeks after embryo transfer

Secondary outcomes

  1. Endometrial Thickness

    Endometrial thickness will be measured by transvaginal ultrasound in the mid-sagittal plane of the uterus as the maximum double-layer endometrial thickness in millimeters.

    Time frame: On the day 1 of endometrial transformation

  2. Endometrial and Sub-endometrial Blood Flow

    Endometrial and sub-endometrial blood flow will be assessed by transvaginal color Doppler or power Doppler ultrasound. Blood flow may be evaluated according to blood flow distribution type and/or three-dimensional Doppler indices, including vascularization index, flow index, and vascularization-flow index.

    Time frame: On the day 1 of endometrial transformation

  3. Clinical Pregnancy Rate

    The proportion of participants with an intrauterine gestational sac confirmed by transvaginal ultrasound after embryo transfer.

    Time frame: 4 to 6 weeks after embryo transfer

  4. Early Miscarriage Rate

    The proportion of participants with clinical pregnancy who experience spontaneous pregnancy loss before 12 weeks of gestation.

    Time frame: From confirmation of clinical pregnancy to 12 weeks of gestation

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Lian R, Wang X, Lin R, Zeng H, Zeng Y, Liu S. Evaluation of granulocyte colony-stimulating factor on the treatment of thin endometrium during frozen-thawed embryo transfer cycles: a retrospective cohort study. Gynecol Endocrinol. 2020 Apr;36(4):370-374. doi: 10.1080/09513590.2019.1658187. Epub 2019 Aug 29. PubMed 31464150 ↗
  • Zhu YC, Sun YX, Shen XY, Jiang Y, Liu JY. Effect of intrauterine perfusion of granular leukocyte-colony stimulating factor on the outcome of frozen embryo transfer. World J Clin Cases. 2021 Oct 26;9(30):9038-9049. doi: 10.12998/wjcc.v9.i30.9038. PubMed 34786386 ↗
  • Liu KE, Hartman M, Hartman A. Management of thin endometrium in assisted reproduction: a clinical practice guideline from the Canadian Fertility and Andrology Society. Reprod Biomed Online. 2019 Jul;39(1):49-62. doi: 10.1016/j.rbmo.2019.02.013. Epub 2019 Mar 20. PubMed 31029557 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared because the study involves sensitive reproductive, pregnancy, delivery, and neonatal clinical information. The current study protocol and informed consent documents do not include a plan for public sharing of individual participant data. De-identified aggregate data may be reported in scientific publications.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Aug 2029, 34 months later.

Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2026
First posted
Jul 9, 2026
StartEst.
Oct 2026
Primary completionEst.
Aug 2029
CompletionEst.
Aug 2029
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07692672
Lead sponsor
Nanjing University
Responsible party
Li-jun Ding (Research Professor, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) — Principal investigator
First posted
Jul 9, 2026
Start date
Oct 2026 (estimated)
Primary completion
Aug 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Jul 9, 2026

Study contacts

Yue Jiang, PhD
Contact
jiangyue85@163.com
+8618262637731
Hui Zhang, PhD
Contact
hellozhanghui@sina.cn
18262637731
Yue Jiang
principal investigator · Nanjing Drum Tower Hospital: Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Granulocyte Colony-Stimulating Factor

Start the discussion